What causes the death of dopaminergic neurons in Parkinson's disease?

D James Surmeier1, Jaime N Guzman, Javier Sanchez-Padilla

  • 1Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. j-surmeier@northwestern.edu

Insights

Parkinson's disease (PD) neuronal loss may stem from cell-specific factors, particularly dopamine (DA) neuron vulnerability due to L-type calcium channel activity. Targeting these channels offers a novel neuroprotective strategy for PD.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Neurodegenerative Diseases

Background:

  • Parkinson's disease (PD) pathogenesis is debated, with focus on pan-cellular factors like genetics and toxins.
  • The specific vulnerability of substantia nigra pars compacta (SNc) dopamine (DA) neurons in PD remains incompletely explained.
  • Cell-specific factors are crucial for understanding the selective neuronal loss observed in PD.

Purpose of the Study:

  • To investigate the cell-specific physiological phenotype of SNc DA neurons contributing to PD vulnerability.
  • To explore the role of L-type calcium channels in SNc DA neuron susceptibility.
  • To identify novel neuroprotective strategies for Parkinson's disease.

Main Methods:

  • Analysis of the physiological characteristics of SNc DA neurons.
  • Examination of calcium channel activity and its downstream effects.
  • Review of existing literature on PD aetiology and potential therapeutic targets.

Main Results:

  • SNc DA neurons exhibit a unique phenotype involving sustained calcium entry through L-type calcium channels during pacemaking.
  • This calcium influx leads to increased mitochondrial oxidant stress and heightened susceptibility to toxins.
  • Cell-specific stress exacerbates the impact of broader cellular challenges (mitochondrial or proteostatic).

Conclusions:

  • L-type calcium channel activity in SNc DA neurons is a key factor in their vulnerability in Parkinson's disease.
  • Targeting these channels with antagonists presents a promising neuroprotective approach.
  • This strategy could complement existing efforts to enhance mitochondrial function in early PD stages.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.